LGL Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

LGL Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Buy	6,970 +6	+0.1%	+$811	0.4%	23
2026 Q1	$889K	Buy	6,964 +540	+8%	+$67.4K	0.37%	28
2025 Q4	$783K	Buy	6,424 +21	+0.3%	+$2.41K	0.33%	27
2025 Q3	$642K	Sell	6,403 -538	-8%	-$48.5K	0.27%	32
2025 Q2	$592K	Sell	6,941 -4,990	-42%	-$398K	0.26%	32
2025 Q1	$968K	Sell	11,931 -6,418	-35%	-$574K	0.47%	23
2024 Q4	$1.65M	Sell	18,349 -1,905	-9%	-$185K	0.24%	34
2024 Q3	$2M	Buy	20,254 +2	+0%	+$197	0.28%	29
2024 Q2	$1.88M	Sell	20,252 -2,221	-10%	-$199K	0.27%	30
2024 Q1	$2.13M	Sell	22,473 -340	-1%	-$31.5K	0.36%	29
2023 Q4	$2.04M	Sell	22,813 -138	-0.6%	-$10.2K	0.28%	30
2023 Q3	$1.68M	Sell	22,951 -763	-3%	-$60.9K	0.29%	29
2023 Q2	$1.97M	Sell	23,714 -650	-3%	-$54.4K	0.34%	25
2023 Q1	$1.86M	Sell	24,364 -3,790	-13%	-$314K	0.32%	25
2022 Q4	$2.34M	Sell	28,154 -1,149	-4%	-$93K	0.42%	23
2022 Q3	$2.32M	Buy	29,303 +13,568	+86%	+$1.14M	0.48%	22
2022 Q2	$1.17M	Buy	15,735 +12,210	+346%	+$917K	0.19%	27
2022 Q1	$317K	Buy	+3,525	New	+$326K	0.04%	74

Other funds holding XBI

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

RAM

Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return

LGL Partners's XBI Position: Q2 2026 in Review

LGL Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.09% in Q2 2026, buying an estimated $811 and bringing the position to 6,970 shares worth $1.1M. The position accounts for 0.4% of the portfolio, ranked #23.

LGL Partners first reported a position in XBI in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.34M in Q4 2022. 393 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

LGL Partners held 6,970 shares of State Street SPDR S&P Biotech ETF worth $1.1M as of Q2 2026.
LGL Partners bought 6 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $811.
State Street SPDR S&P Biotech ETF made up 0.4% of LGL Partners's portfolio in Q2 2026, its #23 holding.
LGL Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 18 quarters since.
LGL Partners's State Street SPDR S&P Biotech ETF position peaked at $2.34M in Q4 2022.
393 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on LGL Partners's 13F filing for Q2 2026, filed 27 Jul 2026.